首页 > 最新文献

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia最新文献

英文 中文
Does the High Renal Resistive Index Reveal an Increased Risk of Acute Kidney Injury? A Protocol for Systematic Review. 高肾阻力指数是否表明急性肾损伤的风险增加?系统评价方案。
Q4 Medicine Pub Date : 2025-04-29 DOI: 10.69097/42-02-2025-02
Giuseppe Cuttone, Giulio Geraci, Luigi La Via, Nicola Sinatra, Maria Rita Stancanelli, Vincenzo Calabrese

Introduction. Acute Kidney Injury (AKI) is a serious complication in critically ill patients associated with significant morbidity and mortality. Early detection and risk stratification remain challenging, particularly in complex conditions such as septic shock where hemodynamic alterations complicate the clinical picture. Renal Resistive Index (RRI), measured through Doppler ultrasonography, has emerged as a promising non-invasive tool for assessing renal hemodynamics and microcirculatory changes. While various studies have investigated the relationship between RRI and AKI, there has not been a comprehensive systematic evaluation of RRI's utility in predicting and assessing AKI in critical care settings. Objective. The main aim is to evaluate the difference in RRI between patients who manifested AKI and patients who did not manifest AKI. Furthermore, the risk of AKI occurrence related to RRI will be computed. Methods. We will perform systematic research in PubMed and Scopus according to the PRISMA Guidelines. We will screen observational studies, with both retrospective and prospective designs on critically ill patients, without sex or age restriction. Expected results. This systematic review is expected to provide a comprehensive and extensive evaluation of the relationship between RRI and AKI. It will be based on observational studies, as RRI is a risk factor not subject to control by the investigator. In addition to assessing the association between RRI and AKI, the study also aims to highlight potential gaps in current knowledge and suggest directions for future research. Conclusions. The present systematic review protocol will include all existing evidence from published articles evaluating the RRI values in patients manifesting or not AKI.

介绍。急性肾损伤(AKI)是危重患者的一种严重并发症,具有显著的发病率和死亡率。早期发现和风险分层仍然具有挑战性,特别是在感染性休克等复杂情况下,血流动力学改变使临床表现复杂化。肾阻力指数(RRI),通过多普勒超声测量,已成为评估肾脏血流动力学和微循环变化的有前途的非侵入性工具。虽然各种研究已经调查了RRI和AKI之间的关系,但尚未对RRI在预测和评估重症监护环境中AKI的效用进行全面系统的评估。目标。主要目的是评估表现为AKI的患者和未表现为AKI的患者之间RRI的差异。此外,将计算与RRI相关的AKI发生的风险。方法。我们将根据PRISMA指南在PubMed和Scopus中进行系统研究。我们将筛选观察性研究,对危重患者进行回顾性和前瞻性设计,没有性别或年龄限制。预期的结果。本系统综述有望对RRI和AKI之间的关系提供全面和广泛的评价。它将基于观察性研究,因为RRI是一种不受研究者控制的风险因素。除了评估RRI和AKI之间的关系外,该研究还旨在强调当前知识的潜在差距,并为未来的研究提出方向。结论。目前的系统评价方案将包括来自已发表文章的所有现有证据,这些文章评估了表现为AKI或不表现为AKI的患者的RRI值。
{"title":"Does the High Renal Resistive Index Reveal an Increased Risk of Acute Kidney Injury? A Protocol for Systematic Review.","authors":"Giuseppe Cuttone, Giulio Geraci, Luigi La Via, Nicola Sinatra, Maria Rita Stancanelli, Vincenzo Calabrese","doi":"10.69097/42-02-2025-02","DOIUrl":"10.69097/42-02-2025-02","url":null,"abstract":"<p><p><b>Introduction.</b> Acute Kidney Injury (AKI) is a serious complication in critically ill patients associated with significant morbidity and mortality. Early detection and risk stratification remain challenging, particularly in complex conditions such as septic shock where hemodynamic alterations complicate the clinical picture. Renal Resistive Index (RRI), measured through Doppler ultrasonography, has emerged as a promising non-invasive tool for assessing renal hemodynamics and microcirculatory changes. While various studies have investigated the relationship between RRI and AKI, there has not been a comprehensive systematic evaluation of RRI's utility in predicting and assessing AKI in critical care settings. <b>Objective.</b> The main aim is to evaluate the difference in RRI between patients who manifested AKI and patients who did not manifest AKI. Furthermore, the risk of AKI occurrence related to RRI will be computed. <b>Methods.</b> We will perform systematic research in PubMed and Scopus according to the PRISMA Guidelines. We will screen observational studies, with both retrospective and prospective designs on critically ill patients, without sex or age restriction. <b>Expected results.</b> This systematic review is expected to provide a comprehensive and extensive evaluation of the relationship between RRI and AKI. It will be based on observational studies, as RRI is a risk factor not subject to control by the investigator. In addition to assessing the association between RRI and AKI, the study also aims to highlight potential gaps in current knowledge and suggest directions for future research. <b>Conclusions.</b> The present systematic review protocol will include all existing evidence from published articles evaluating the RRI values in patients manifesting or not AKI.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is Iohexol a Possible Method for Estimating Glomerular Filtration Rate? 碘己醇是估计肾小球滤过率的可能方法吗?
Q4 Medicine Pub Date : 2025-04-29 DOI: 10.69097/42-02-2025-03
Fabrizio Cristiano, Guillermo Rosa-Diez, Carlos Guido Musso, Jenny Cristiano

The measurement of glomerular filtration rate (GFR) is essential in diagnosing and managing chronic kidney disease (CKD) and autosomal dominant polycystic kidney disease (ADPKD), both requiring precise renal function assessment. Traditionally, GFR has been estimated using endogenous markers like creatinine and cystatin C, though these can be inaccurate due to factors unrelated to kidney function, such as muscle mass and diet. The iohexol clearance method provides a more accurate and less invasive alternative to traditional markers like inulin or radioactive markers. Iohexol, a non-ionic, water-soluble contrast agent, is exclusively eliminated by glomerular filtration, making it highly suitable for direct GFR estimation. This paper describes procedures for iohexol clearance, involving defined-interval blood samples after intravenous administration. In patients with normal renal function, sampling intervals are more frequent, while in advanced CKD patients, including those with ADPKD, slower iohexol elimination requires wider intervals to ensure accurate clearance analysis. Iohexol has demonstrated high precision and reproducibility, even compared to other markers. Research supports using iohexol to monitor CKD and ADPKD progression effectively. Particularly in ADPKD, iohexol detects subtle but clinically significant GFR changes, even in early disease stages, making it valuable for evaluating targeted therapies. However, iohexol use is limited to specialized centers due to high costs and strict protocols. Its implementation in advanced European healthcare facilities underscores its efficacy, providing reliable GFR estimates that enhance nephrology practice, despite some limitations.

肾小球滤过率(GFR)的测量在慢性肾病(CKD)和常染色体显性多囊肾病(ADPKD)的诊断和治疗中是必不可少的,两者都需要精确的肾功能评估。传统上,GFR是用内源性标志物如肌酐和胱抑素C来估计的,但由于与肾功能无关的因素,如肌肉质量和饮食,这些指标可能不准确。碘己醇清除方法提供了一种比菊粉或放射性标记等传统标记更准确、侵入性更小的替代方法。碘己醇是一种非离子型水溶性造影剂,完全通过肾小球滤过消除,因此非常适合直接估计GFR。本文描述了碘己醇清除的程序,包括静脉给药后确定间隔的血液样本。在肾功能正常的患者中,采样间隔更频繁,而在晚期CKD患者中,包括ADPKD患者,较慢的碘己醇消除需要更宽的间隔,以确保准确的清除率分析。即使与其他标记物相比,碘己醇也具有很高的精度和可重复性。研究支持使用碘己醇有效监测CKD和ADPKD进展。特别是在ADPKD中,iohexol可以检测细微但具有临床意义的GFR变化,即使在疾病的早期阶段,这使得它对评估靶向治疗有价值。然而,由于高成本和严格的协议,碘己醇的使用仅限于专门的中心。它在先进的欧洲医疗机构的实施强调了它的功效,提供可靠的GFR估计,加强肾脏学实践,尽管有一些限制。
{"title":"Is Iohexol a Possible Method for Estimating Glomerular Filtration Rate?","authors":"Fabrizio Cristiano, Guillermo Rosa-Diez, Carlos Guido Musso, Jenny Cristiano","doi":"10.69097/42-02-2025-03","DOIUrl":"10.69097/42-02-2025-03","url":null,"abstract":"<p><p>The measurement of glomerular filtration rate (GFR) is essential in diagnosing and managing chronic kidney disease (CKD) and autosomal dominant polycystic kidney disease (ADPKD), both requiring precise renal function assessment. Traditionally, GFR has been estimated using endogenous markers like creatinine and cystatin C, though these can be inaccurate due to factors unrelated to kidney function, such as muscle mass and diet. The iohexol clearance method provides a more accurate and less invasive alternative to traditional markers like inulin or radioactive markers. Iohexol, a non-ionic, water-soluble contrast agent, is exclusively eliminated by glomerular filtration, making it highly suitable for direct GFR estimation. This paper describes procedures for iohexol clearance, involving defined-interval blood samples after intravenous administration. In patients with normal renal function, sampling intervals are more frequent, while in advanced CKD patients, including those with ADPKD, slower iohexol elimination requires wider intervals to ensure accurate clearance analysis. Iohexol has demonstrated high precision and reproducibility, even compared to other markers. Research supports using iohexol to monitor CKD and ADPKD progression effectively. Particularly in ADPKD, iohexol detects subtle but clinically significant GFR changes, even in early disease stages, making it valuable for evaluating targeted therapies. However, iohexol use is limited to specialized centers due to high costs and strict protocols. Its implementation in advanced European healthcare facilities underscores its efficacy, providing reliable GFR estimates that enhance nephrology practice, despite some limitations.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Boosting Tolvaptan Tolerance in ADPKD: Low-Dose Hydrochlorothiazide Improves Patient Well-being Without Compromising Efficacy - A Case Report. 提高ADPKD患者托伐普坦耐受性:低剂量氢氯噻嗪在不影响疗效的情况下改善患者的健康-一个病例报告。
Q4 Medicine Pub Date : 2025-04-29 DOI: 10.69097/42-02-2025-06
Kristiana Kola, Martina Catania, Liliana Italia De Rosa, Matteo Brambilla Pisoni, Sara Farinone, Paola Maiucchi, Micaela Petrone, Paolo Manunta, Giuseppe Vezzoli, Maria Teresa Sciarrone Alibrandi

ADPKD is the most common inherited kidney disorder, marked by numerous renal cysts, increased total kidney volume and progressive renal function decline. Mutations in the PKD1 and PKD2 genes, leading to altered cAMP signaling, drive cyst growth. Elevated antidiuretic hormone (ADH) levels further exacerbate cystogenesis. Tolvaptan, a vasopressin V2 receptor antagonist, is the only approved treatment for slowing ADPKD progression, but its use often results in significant polyuria and thirst, affecting patient quality of life. This case report presents a 31-year-old female with ADPKD, classified as Mayo Class 1D, who showed improved tolerance to tolvaptan after co-administering low-dose hydrochlorothiazide (HCT). The patient experienced a significant reduction in polyuria and thirst while maintaining stable kidney function over four years. The annual decline in eGFR was less than expected for her disease class and improved compared to the first year of tolvaptan therapy. This case suggests that HCT may enhance tolvaptan tolerability without reducing its efficacy. Ongoing studies, such as the HYDRO-PROTECT trial, aim to further explore the benefits of combining HCT with tolvaptan in ADPKD management.

ADPKD是最常见的遗传性肾脏疾病,其特点是肾囊肿多,肾总容量增大,肾功能进行性下降。PKD1和PKD2基因的突变导致cAMP信号的改变,从而驱动囊肿的生长。升高的抗利尿激素(ADH)水平进一步加剧膀胱形成。抗利尿激素V2受体拮抗剂Tolvaptan是唯一被批准用于减缓ADPKD进展的药物,但其使用经常导致明显的多尿和口渴,影响患者的生活质量。本病例报告报告了一名31岁的ADPKD女性,被归类为Mayo 1D级,在联合使用低剂量氢氯噻嗪(HCT)后,对托伐普坦的耐受性得到改善。在四年多的时间里,患者的多尿和口渴明显减少,同时保持了稳定的肾功能。在她的疾病类别中,eGFR的年度下降低于预期,与托伐普坦治疗的第一年相比有所改善。本病例提示HCT可增强托伐普坦耐受性而不降低其疗效。正在进行的研究,如HYDRO-PROTECT试验,旨在进一步探索HCT与托伐普坦联合治疗ADPKD的益处。
{"title":"Boosting Tolvaptan Tolerance in ADPKD: Low-Dose Hydrochlorothiazide Improves Patient Well-being Without Compromising Efficacy - A Case Report.","authors":"Kristiana Kola, Martina Catania, Liliana Italia De Rosa, Matteo Brambilla Pisoni, Sara Farinone, Paola Maiucchi, Micaela Petrone, Paolo Manunta, Giuseppe Vezzoli, Maria Teresa Sciarrone Alibrandi","doi":"10.69097/42-02-2025-06","DOIUrl":"https://doi.org/10.69097/42-02-2025-06","url":null,"abstract":"<p><p>ADPKD is the most common inherited kidney disorder, marked by numerous renal cysts, increased total kidney volume and progressive renal function decline. Mutations in the PKD1 and PKD2 genes, leading to altered cAMP signaling, drive cyst growth. Elevated antidiuretic hormone (ADH) levels further exacerbate cystogenesis. Tolvaptan, a vasopressin V2 receptor antagonist, is the only approved treatment for slowing ADPKD progression, but its use often results in significant polyuria and thirst, affecting patient quality of life. This case report presents a 31-year-old female with ADPKD, classified as Mayo Class 1D, who showed improved tolerance to tolvaptan after co-administering low-dose hydrochlorothiazide (HCT). The patient experienced a significant reduction in polyuria and thirst while maintaining stable kidney function over four years. The annual decline in eGFR was less than expected for her disease class and improved compared to the first year of tolvaptan therapy. This case suggests that HCT may enhance tolvaptan tolerability without reducing its efficacy. Ongoing studies, such as the HYDRO-PROTECT trial, aim to further explore the benefits of combining HCT with tolvaptan in ADPKD management.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatorenal Syndrome - AKI in Decompensated Liver Disease: Clinical Characteristics, Risk Factors, Ultrasound Applications, and Outcomes. 肝肾综合征-失代偿性肝病的AKI:临床特征、危险因素、超声应用和结果
Q4 Medicine Pub Date : 2025-04-29 DOI: 10.69097/42-02-2025-11
Yarramachu Dharanidhar Reddy, K Sai Sindhu Singh, Pavuluri Lakshmi Aishwarya, J K Jayaram, Indhumathi Elayaperumal

Background. Acute kidney injury (AKI) is a common and serious complication in patients with decompensated liver disease (DLD), often resulting from ischemic acute tubular necrosis or hepatorenal syndrome. This study examines the role of biochemical markers and ultrasound parameters, such as right atrial pressure, right ventricular hypertrophy, inferior vena cava diameter, hepatic venous flow dynamics, left ventricular diastolic dysfunction, the E/e' ratio, renal peak systolic velocity, renal end-diastolic velocity, and renal resistive index (RI), in predicting AKI severity and outcomes. Methods. A prospective observational study was conducted on 50 DLD patients with AKI, admitted to a tertiary care Hospital. Biochemical parameters including serum creatinine, bilirubin, and albumin along with ultrasound parameters were assessed. AKI was classified according to KDIGO criteria, and renal recovery and mortality were monitored. Diagnostic accuracy was evaluated through ROC analysis. Results. 30% of patients had stage 3 AKI, with 60% of them being male (average age 54 ± 12 years). Stage 3 AKI was a significant predictor of mortality (OR 3.5, p < 0.001), along with renal resistive index (OR 2.8, p = 0.003). ROC analysis showed that serum creatinine and the E/e' ratio, along with the RI, were significant predictors for AKI severity and mortality. Renal recovery occurred in 58%. Conclusion. The simultaneous assessment of clinical, biochemical, and ultrasound parameters enhances the prediction of AKI severity and patient outcomes in DLD. This approach facilitates earlier detection and better management of AKI in this population.

背景。急性肾损伤(AKI)是失代偿性肝病(DLD)患者常见且严重的并发症,通常由缺血性急性肾小管坏死或肝肾综合征引起。本研究探讨生化指标和超声参数的作用,如右心房压、右心室肥厚、下腔静脉直径、肝静脉血流动力学、左心室舒张功能障碍、E/ E比值、肾收缩期峰值速度、肾舒张末期速度和肾阻力指数(RI),在预测AKI严重程度和预后中的作用。方法。一项前瞻性观察研究对50名住院三级医院的DLD合并AKI患者进行了研究。生化参数包括血清肌酐、胆红素和白蛋白以及超声参数进行评估。根据KDIGO标准对AKI进行分类,并监测肾脏恢复和死亡率。通过ROC分析评估诊断准确性。结果:30%的患者为3期AKI,其中60%为男性(平均年龄54±12岁)。3期AKI是死亡率的重要预测因子(OR 3.5, p < 0.001),以及肾抵抗指数(OR 2.8, p = 0.003)。ROC分析显示,血清肌酐和E/ E比值以及RI是AKI严重程度和死亡率的重要预测因子。肾恢复率为58%。结论。同时评估临床、生化和超声参数可以提高对DLD患者AKI严重程度和预后的预测。这种方法有助于在这一人群中更早地发现和更好地管理AKI。
{"title":"Hepatorenal Syndrome - AKI in Decompensated Liver Disease: Clinical Characteristics, Risk Factors, Ultrasound Applications, and Outcomes.","authors":"Yarramachu Dharanidhar Reddy, K Sai Sindhu Singh, Pavuluri Lakshmi Aishwarya, J K Jayaram, Indhumathi Elayaperumal","doi":"10.69097/42-02-2025-11","DOIUrl":"https://doi.org/10.69097/42-02-2025-11","url":null,"abstract":"<p><p><b>Background.</b> Acute kidney injury (AKI) is a common and serious complication in patients with decompensated liver disease (DLD), often resulting from ischemic acute tubular necrosis or hepatorenal syndrome. This study examines the role of biochemical markers and ultrasound parameters, such as right atrial pressure, right ventricular hypertrophy, inferior vena cava diameter, hepatic venous flow dynamics, left ventricular diastolic dysfunction, the E/e' ratio, renal peak systolic velocity, renal end-diastolic velocity, and renal resistive index (RI), in predicting AKI severity and outcomes. <b>Methods.</b> A prospective observational study was conducted on 50 DLD patients with AKI, admitted to a tertiary care Hospital. Biochemical parameters including serum creatinine, bilirubin, and albumin along with ultrasound parameters were assessed. AKI was classified according to KDIGO criteria, and renal recovery and mortality were monitored. Diagnostic accuracy was evaluated through ROC analysis. <b>Results.</b> 30% of patients had stage 3 AKI, with 60% of them being male (average age 54 ± 12 years). Stage 3 AKI was a significant predictor of mortality (OR 3.5, p < 0.001), along with renal resistive index (OR 2.8, p = 0.003). ROC analysis showed that serum creatinine and the E/e' ratio, along with the RI, were significant predictors for AKI severity and mortality. Renal recovery occurred in 58%. <b>Conclusion.</b> The simultaneous assessment of clinical, biochemical, and ultrasound parameters enhances the prediction of AKI severity and patient outcomes in DLD. This approach facilitates earlier detection and better management of AKI in this population.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Peritoneal Dialysis Catheter Design: Variants and Clinical Implications]. [腹膜透析导管设计:变异和临床意义]。
Q4 Medicine Pub Date : 2025-04-29 DOI: 10.69097/42-02-2025-04
Luca Nardelli, Antonio Scalamogna, Giuseppe Castellano

The success of peritoneal dialysis (PD) relies imperatively on the presence of a safe and well-functioning peritoneal access. The ideal catheter should be easy to position and durable, comfortable and practical to use, have minimal aesthetic impact and present low infectious and mechanical complications. Originally, the catheter that came closest to these characteristics was designed by Tenckhoff at the end of the 1960s. Over the next fifty years, different types of devices were developed with the aim of improving their efficiency and at the same time reducing the associated complications. Overall, none of these catheters has demonstrated a clear superiority over the Tenckhoff catheter and yet up to 30% of PD discontinuations are due to access-related complications. However, nowadays the wide range of existing models bestow the possibility of a personalized choice. This approach, together with the placement technique and the experience of the centre, would allow maximizing the benefits deriving from specific features of the PD catheter in relation to peculiar conditions of the recipient. Therefore, for clinicians involved in the positioning and care of peritoneal access, understanding the principles underlying the different configurations of the PD catheter is necessary to establish a "case by case" approach.

腹膜透析(PD)的成功依赖于一个安全和功能良好的腹膜通道的存在。理想的导管应易于定位,耐用,使用舒适实用,美观影响最小,感染和机械并发症低。最初,最接近这些特征的导管是由Tenckhoff在20世纪60年代末设计的。在接下来的五十年里,不同类型的设备被开发出来,目的是提高效率,同时减少相关的并发症。总的来说,这些导管都没有表现出明显优于Tenckhoff导管,但高达30%的PD中断是由于与通路相关的并发症。然而,如今广泛的现有模式赋予了个性化选择的可能性。这种方法,加上放置技术和中心的经验,将允许PD导管的特定特征在接受者的特殊情况下获得最大的好处。因此,对于参与腹膜通路定位和护理的临床医生来说,了解PD导管不同配置的原理对于建立“具体情况具体分析”的方法是必要的。
{"title":"[Peritoneal Dialysis Catheter Design: Variants and Clinical Implications].","authors":"Luca Nardelli, Antonio Scalamogna, Giuseppe Castellano","doi":"10.69097/42-02-2025-04","DOIUrl":"https://doi.org/10.69097/42-02-2025-04","url":null,"abstract":"<p><p>The success of peritoneal dialysis (PD) relies imperatively on the presence of a safe and well-functioning peritoneal access. The ideal catheter should be easy to position and durable, comfortable and practical to use, have minimal aesthetic impact and present low infectious and mechanical complications. Originally, the catheter that came closest to these characteristics was designed by Tenckhoff at the end of the 1960s. Over the next fifty years, different types of devices were developed with the aim of improving their efficiency and at the same time reducing the associated complications. Overall, none of these catheters has demonstrated a clear superiority over the Tenckhoff catheter and yet up to 30% of PD discontinuations are due to access-related complications. However, nowadays the wide range of existing models bestow the possibility of a personalized choice. This approach, together with the placement technique and the experience of the centre, would allow maximizing the benefits deriving from specific features of the PD catheter in relation to peculiar conditions of the recipient. Therefore, for clinicians involved in the positioning and care of peritoneal access, understanding the principles underlying the different configurations of the PD catheter is necessary to establish a \"case by case\" approach.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lymphoid Peritoneal Fluid as a Variant of Chylous-Like Effluent in Peritoneal Dialysis: Proposal for a New Diagnostic Term. 淋巴样腹膜液是腹膜透析中乳糜样流出物的一种变体:提出一个新的诊断术语。
Q4 Medicine Pub Date : 2025-04-29 DOI: 10.69097/42-02-2025-09
Nigel Fernandez-Carlos, Maria L Ocampo, Carlos G Musso, Fabrizio Cristiano, Gustavo Aroca-Martinez, Maria C Giordani

The cloudy bag in peritoneal dialysis is generally associated with infectious peritonitis and non-infectious etiologies. These cloudy bags may have increased cellularity or low/acellular counts. In the case of low cell count, the concomitant detection of fibrin or fat can provide guidance on its etiology. The cloudy peritoneal bag with a whitish appearance is usually due to its high fat content (chyloperitoneum). The etiologies include pharmacological, traumatic or inflammatory causes. The elevated fatty component in chyloperitoneum may be triglycerides (chylous), cholesterol (pseudochylous) or lymph. We present the case of a patient with stage 5 chronic kidney disease (CKD). He starts continuous ambulatory peritoneal dialysis and presents turbid but acellular peritoneal effluent with chylous appearance, negative cultures, and low levels of triglycerides and cholesterol on physicochemical evaluation. It doesn't meet the criteria for chylous or pseudochylous fluid, which is why the term lymphoid fluid is here proposed to describe it, because of its resemblance to lymphatic fluid in color. To our knowledge, this is the first case in the literature to report this effluent (milky-looking fluid without high levels of triglycerides or cholesterol) and to propose a specific term to describe it.

腹膜透析中的浑浊袋通常与感染性腹膜炎和非感染性病因有关。这些浑浊袋可能有细胞增多或低/无细胞计数。在低细胞计数的情况下,同时检测纤维蛋白或脂肪可以为其病因提供指导。浑浊的腹膜袋呈白色,通常是由于其脂肪含量高(乳糜腹膜)。病因包括药理学、创伤性或炎症性原因。乳糜腹膜中升高的脂肪成分可能是甘油三酯(乳糜)、胆固醇(假性乳糜)或淋巴。我们提出的病例患者的5期慢性肾脏疾病(CKD)。他开始持续的动态腹膜透析,出现浑浊但无细胞的腹膜流出物,乳糜样,培养阴性,物理化学评价甘油三酯和胆固醇水平低。它不符合乳糜液或假性乳糜液的标准,这就是为什么这里建议用淋巴样液来描述它,因为它在颜色上与淋巴液相似。据我们所知,这是文献中第一例报道这种流出物(乳白色液体,没有高水平的甘油三酯或胆固醇),并提出一个具体的术语来描述它。
{"title":"Lymphoid Peritoneal Fluid as a Variant of Chylous-Like Effluent in Peritoneal Dialysis: Proposal for a New Diagnostic Term.","authors":"Nigel Fernandez-Carlos, Maria L Ocampo, Carlos G Musso, Fabrizio Cristiano, Gustavo Aroca-Martinez, Maria C Giordani","doi":"10.69097/42-02-2025-09","DOIUrl":"10.69097/42-02-2025-09","url":null,"abstract":"<p><p>The cloudy bag in peritoneal dialysis is generally associated with infectious peritonitis and non-infectious etiologies. These cloudy bags may have increased cellularity or low/acellular counts. In the case of low cell count, the concomitant detection of fibrin or fat can provide guidance on its etiology. The cloudy peritoneal bag with a whitish appearance is usually due to its high fat content (chyloperitoneum). The etiologies include pharmacological, traumatic or inflammatory causes. The elevated fatty component in chyloperitoneum may be triglycerides (chylous), cholesterol (pseudochylous) or lymph. We present the case of a patient with stage 5 chronic kidney disease (CKD). He starts continuous ambulatory peritoneal dialysis and presents turbid but acellular peritoneal effluent with chylous appearance, negative cultures, and low levels of triglycerides and cholesterol on physicochemical evaluation. It doesn't meet the criteria for chylous or pseudochylous fluid, which is why the term lymphoid fluid is here proposed to describe it, because of its resemblance to lymphatic fluid in color. To our knowledge, this is the first case in the literature to report this effluent (milky-looking fluid without high levels of triglycerides or cholesterol) and to propose a specific term to describe it.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment Optimization and Standard of Care Adherence in CKD Primary Care: the TOSCA-CKD project. CKD初级护理的治疗优化和护理依从性标准:TOSCA-CKD项目。
Q4 Medicine Pub Date : 2025-04-29 DOI: 10.69097/42-02-2025-10
Francesco Pesce, Domenico Pasculli, Giuseppe Castellano, Luca De Nicola, Giovanni Gambaro, Vincenzo Panichi, Domenico Santoro, Francesca Viazzi, Monica Zanella, Loreto Gesualdo

Background. Effective collaboration between general practitioners (GPs) and nephrologists is crucial for optimizing the management of chronic kidney disease (CKD). The TOSCA-CKD project (Treatment Optimization and Standard of Care Adherence in CKD Primary Care) aimed to evaluate the implementation of guidelines and the use of nephroprotective therapies in primary care. Methods. Clinical data were collected from the medical records of GPs across 12 Italian regions. The data were analyzed at baseline (T0) and after 6 months (T6) of collaboration with nephrologists. During this observational period, GPs were involved in remote education programs, which included expert-led webinars and clinical case-based learning. Results. A total of 76 GPs and 9 nephrologists were involved in the study, evaluating a cohort of 124,759 patients. There was an increase of 23.3% in the uACR test from T0 to T6 (3.0% vs. 3.7%; p < 0.001). Similarly, there was an increase of 15.2% in the use of eGFR from T0 to T6 (29.7% vs. 34.2%; p < 0.001). The rate of CKD diagnosis increased by 17.5% among patients with eGFR < 60 mL/min/1.73 m² (from 4% to 4.7%) and by 40% among patients with ACR > 30 mg/g (from 0.5% to 0.7%). The use of ACEi/ARBs remained stable at approximately 50%, while the treatment with SGLT2i, the new standard of care according to the current CKD guidelines, increased by 29.8% (from 4.7% to 6.1%). Conclusions. The TOSCA-CKD project demonstrated that GPs' remote educational program and a structured co-management approach significantly enhanced the early identification and improved the management of CKD in primary care.

背景。全科医生(gp)和肾病学家之间的有效合作对于优化慢性肾脏疾病(CKD)的管理至关重要。TOSCA-CKD项目(CKD初级保健的治疗优化和护理依从性标准)旨在评估指南的实施和初级保健中肾保护疗法的使用。方法。临床数据是从意大利12个地区的全科医生的医疗记录中收集的。数据在基线(T0)和与肾病学家合作6个月(T6)后进行分析。在观察期间,全科医生参与了远程教育项目,其中包括专家领导的网络研讨会和基于临床病例的学习。结果。共有76名全科医生和9名肾病学家参与了这项研究,对124,759名患者进行了评估。从T0到T6, uACR试验增加了23.3% (3.0% vs. 3.7%;P < 0.001)。同样,从T0到T6, eGFR的使用增加了15.2% (29.7% vs. 34.2%;P < 0.001)。在eGFR < 60 mL/min/1.73 m²的患者中,CKD诊断率增加了17.5%(从4%增加到4.7%),在ACR < 30 mg/g的患者中,CKD诊断率增加了40%(从0.5%增加到0.7%)。ACEi/ arb的使用保持稳定在50%左右,而SGLT2i治疗,根据当前CKD指南的新护理标准,增加了29.8%(从4.7%增加到6.1%)。结论。TOSCA-CKD项目表明,全科医生的远程教育计划和结构化的共同管理方法显著提高了初级保健中CKD的早期识别和管理。
{"title":"Treatment Optimization and Standard of Care Adherence in CKD Primary Care: the TOSCA-CKD project.","authors":"Francesco Pesce, Domenico Pasculli, Giuseppe Castellano, Luca De Nicola, Giovanni Gambaro, Vincenzo Panichi, Domenico Santoro, Francesca Viazzi, Monica Zanella, Loreto Gesualdo","doi":"10.69097/42-02-2025-10","DOIUrl":"https://doi.org/10.69097/42-02-2025-10","url":null,"abstract":"<p><p><b>Background.</b> Effective collaboration between general practitioners (GPs) and nephrologists is crucial for optimizing the management of chronic kidney disease (CKD). The TOSCA-CKD project (Treatment Optimization and Standard of Care Adherence in CKD Primary Care) aimed to evaluate the implementation of guidelines and the use of nephroprotective therapies in primary care. <b>Methods.</b> Clinical data were collected from the medical records of GPs across 12 Italian regions. The data were analyzed at baseline (T0) and after 6 months (T6) of collaboration with nephrologists. During this observational period, GPs were involved in remote education programs, which included expert-led webinars and clinical case-based learning. <b>Results.</b> A total of 76 GPs and 9 nephrologists were involved in the study, evaluating a cohort of 124,759 patients. There was an increase of 23.3% in the uACR test from T0 to T6 (3.0% vs. 3.7%; p < 0.001). Similarly, there was an increase of 15.2% in the use of eGFR from T0 to T6 (29.7% vs. 34.2%; p < 0.001). The rate of CKD diagnosis increased by 17.5% among patients with eGFR < 60 mL/min/1.73 m² (from 4% to 4.7%) and by 40% among patients with ACR > 30 mg/g (from 0.5% to 0.7%). The use of ACEi/ARBs remained stable at approximately 50%, while the treatment with SGLT2i, the new standard of care according to the current CKD guidelines, increased by 29.8% (from 4.7% to 6.1%). <b>Conclusions.</b> The TOSCA-CKD project demonstrated that GPs' remote educational program and a structured co-management approach significantly enhanced the early identification and improved the management of CKD in primary care.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Presentation of the Triveneto Exit-Site Infections Register (RESIsT) and Warm-Up of Peritoneal Dialysis Centers]. [介绍腹膜透析中心的Triveneto出口感染登记(RESIsT)和预热]。
Q4 Medicine Pub Date : 2025-04-29 DOI: 10.69097/42-02-2025-12
Antonino Previti, Pietro Manuel Ferraro, Elisa De Tomi, Giovanni Gambaro

Infections related to the peritoneal catheter, whether of the exit-site or of the subcutaneous tunnel (ESI), are a predisposing factor for the development of peritonitis. The regions of Friuli-Venezia Giulia, Trentino-Alto Adige and Veneto (Triveneto) have started a collaborative network to spread knowledge and optimize the use of peritoneal dialysis. The need to collect and aggregate ESI data emerged, therefore the project of a Register of ESIs of the Triveneto (RESIsT) was launched. This work analyzes the preparation and testing phase of the Registry.

与腹膜导管相关的感染,无论是出口部位还是皮下隧道(ESI),都是腹膜炎发展的易感因素。弗留利-威尼斯-朱利亚、特伦蒂诺-上阿迪杰和威尼托地区已经启动了一个协作网络,以传播知识和优化腹膜透析的使用。收集和汇总ESI数据的需求出现了,因此启动了Triveneto ESI登记册(RESIsT)项目。这项工作分析了注册表的准备和测试阶段。
{"title":"[Presentation of the Triveneto Exit-Site Infections Register (RESIsT) and Warm-Up of Peritoneal Dialysis Centers].","authors":"Antonino Previti, Pietro Manuel Ferraro, Elisa De Tomi, Giovanni Gambaro","doi":"10.69097/42-02-2025-12","DOIUrl":"https://doi.org/10.69097/42-02-2025-12","url":null,"abstract":"<p><p>Infections related to the peritoneal catheter, whether of the exit-site or of the subcutaneous tunnel (ESI), are a predisposing factor for the development of peritonitis. The regions of Friuli-Venezia Giulia, Trentino-Alto Adige and Veneto (Triveneto) have started a collaborative network to spread knowledge and optimize the use of peritoneal dialysis. The need to collect and aggregate ESI data emerged, therefore the project of a Register of ESIs of the Triveneto (RESIsT) was launched. This work analyzes the preparation and testing phase of the Registry.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[New Genetic Variants Involved in the Pathogenesis of Autosomal Dominant Alport Syndrome: A Familial Case Report]. [常染色体显性阿尔波特综合征发病机制的新遗传变异:家族病例报告]。
Q4 Medicine Pub Date : 2025-04-29 DOI: 10.69097/42-02-2025-07
Sandra La Rosa, Stefania Pesce, Simona Lombardo, Marilena C Fiorino, Antonio Granata

Alport syndrome is a hereditary disorder characterized by hematuria, proteinuria and progressive renal failure, frequently associated with extrarenal manifestations. The pathogenic variants of the COL4A5 gene are associated with X-linked Alport syndrome while those of the COL4A3 and COL4A4 genes are associated with the autosomal recessive (AR) or dominant (AD) form. The disease is characterized by considerable phenotypic variability linked to the different genes involved and the different mutations present, so the symptoms manifest themselves in different frequencies depending on the case. The existence of an autosomal dominant form of Alport syndrome has been identified in recent years thanks to next generation gene sequencing (NGS) techniques which have made it possible to highlight unknown genetic variants of Alport syndrome. The family studied by us presents concomitant heterozygous alterations of the COL4A3 genes (c.1029+5G>A with MAF 0 and c.3211-7A>G with MAF 1:100000), heterozygous alterations of the MTHFR gene (both C677T and A1298C) and homozygous alteration of the PAI-1 gene. While the variant c.3211-7A>G, as shown by genetic databases (ClinVar), appears to be benign, the intronic variant c.1029+5G>A (caused by exon skipping) can be classified as pathogenic due to its characteristics and the fact that it co-segregates with the phenotype within the family. The histological data, in one of the sisters, highlighted the presence of a discrete global glomerular sclerosis and the ultrastructural investigation a thinning of the glomerular basement membrane. New mutational variants of the COL4A3 gene may play a role as risk variants for the development of chronic kidney disease.

Alport综合征是一种以血尿、蛋白尿和进行性肾衰竭为特征的遗传性疾病,常伴有肾外表现。COL4A5基因的致病变异与x连锁Alport综合征有关,而COL4A3和COL4A4基因的致病变异与常染色体隐性(AR)或显性(AD)形式有关。这种疾病的特点是与不同的基因和不同的突变相关的相当大的表型变异性,因此症状根据病例以不同的频率表现出来。近年来,由于下一代基因测序(NGS)技术的发展,发现了一种常染色体显性的阿尔波特综合征,这使得发现未知的阿尔波特综合征遗传变异成为可能。我们研究的家族存在COL4A3基因的杂合性改变(c.1029+5G>A与MAF 0和c.3211-7A>G与MAF 1:10万),MTHFR基因的杂合性改变(C677T和A1298C)和PAI-1基因的纯合性改变。遗传数据库(ClinVar)显示,c.3211-7A>G变异似乎是良性的,而内含子变异c.1029+5G>A(由外显子跳变引起)由于其特征以及它与家族内表型共分离的事实,可以归类为致病性的。其中一名姐妹的组织学资料强调了离散性全局肾小球硬化的存在,超微结构检查显示肾小球基底膜变薄。COL4A3基因的新突变变体可能在慢性肾脏疾病的发展中发挥风险变异的作用。
{"title":"[New Genetic Variants Involved in the Pathogenesis of Autosomal Dominant Alport Syndrome: A Familial Case Report].","authors":"Sandra La Rosa, Stefania Pesce, Simona Lombardo, Marilena C Fiorino, Antonio Granata","doi":"10.69097/42-02-2025-07","DOIUrl":"10.69097/42-02-2025-07","url":null,"abstract":"<p><p>Alport syndrome is a hereditary disorder characterized by hematuria, proteinuria and progressive renal failure, frequently associated with extrarenal manifestations. The pathogenic variants of the COL4A5 gene are associated with X-linked Alport syndrome while those of the COL4A3 and COL4A4 genes are associated with the autosomal recessive (AR) or dominant (AD) form. The disease is characterized by considerable phenotypic variability linked to the different genes involved and the different mutations present, so the symptoms manifest themselves in different frequencies depending on the case. The existence of an autosomal dominant form of Alport syndrome has been identified in recent years thanks to next generation gene sequencing (NGS) techniques which have made it possible to highlight unknown genetic variants of Alport syndrome. The family studied by us presents concomitant heterozygous alterations of the COL4A3 genes (c.1029+5G>A with MAF 0 and c.3211-7A>G with MAF 1:100000), heterozygous alterations of the MTHFR gene (both C677T and A1298C) and homozygous alteration of the PAI-1 gene. While the variant c.3211-7A>G, as shown by genetic databases (ClinVar), appears to be benign, the intronic variant c.1029+5G>A (caused by exon skipping) can be classified as pathogenic due to its characteristics and the fact that it co-segregates with the phenotype within the family. The histological data, in one of the sisters, highlighted the presence of a discrete global glomerular sclerosis and the ultrastructural investigation a thinning of the glomerular basement membrane. New mutational variants of the COL4A3 gene may play a role as risk variants for the development of chronic kidney disease.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Gout From the Corpus Hippocraticum to the Renaissance: The Role of Galen]. [痛风从希波克拉底文集到文艺复兴:盖伦的角色]。
Q4 Medicine Pub Date : 2025-04-29 DOI: 10.69097/42-02-2025-14
Natale Gaspare De Santo, Carmela Bisaccia, Luca Salvatore De Santo

Gout is a common, complex, systemic and well-studied form of chronic inflammatory arthritis due to deposition of sodium monourate crystals in peripheral joints and periarticular tissues driven by hyperuricemia. Gout is the oldest recorded inflammatory arthritis to affect humankind, with roots stretching back to 2640 BCE. To establish the timeline of gout from the Corpus Hippocraticum to the Renaissance, this study focuses on Galen (129-c.215 CE). A princeps English edition of Galen's works is still lacking; therefore, this paper provides a translation of the paragraph on gout from the Latin edition [12] by Carolus Gottlob Kühn (Leipzig, 1821-1833). Galen departs from Hippocrates and displays a vast knowledge of pathogenesis, symptomatology, clinical course, differential diagnosis, therapeutic skills and prognostication. In Galen's view, gout is due to fluid overflow that infiltrates nerves and causes pain. Overflowing fluid may be blood, phlegm, or a mixture of bile, blood, and phlegm. The prevailing humor is crude, mucous, and thick, and by residing in the joint, causes tophi. The nature of infiltrating humor can be diagnosed through color of the joint, symptoms, effects of heat and cold, effects of drugs, and information related to age, diet, quantity and quality of exercise, attitude towards baths of the patient. Treatment, according to Galen, required immediate bloodletting by venesection at the elbow, which could be repeated. Purges, enemas, and/or emetics are additionally needed to evacuate the humor(s). Poultices played a role draining the humor(s) as well as for their emollient-softening properties.

痛风是一种常见的、复杂的、全身性的、研究充分的慢性炎症性关节炎形式,它是由高尿酸血症驱动的单酸钠晶体在周围关节和关节周围组织沉积引起的。痛风是影响人类的最古老的炎症性关节炎,其根源可以追溯到公元前2640年。为了确定从希波克拉底文集到文艺复兴时期痛风的时间线,本研究将重点放在盖伦(129-c.215)身上CE)。盖伦著作的主要英文版至今仍未出版;因此,本文提供了Carolus Gottlob k hn (Leipzig, 1821-1833)的拉丁版[12]中关于痛风的段落的翻译。盖伦从希波克拉底出发,在发病机理、症状学、临床过程、鉴别诊断、治疗技巧和预后方面展现了丰富的知识。在盖伦看来,痛风是由于液体溢出渗入神经而引起疼痛。溢液可能是血、痰,也可能是胆汁、血和痰的混合物。主要的幽默是粗糙的、黏液状的、粘稠的,由于存在于关节中,引起痛风。浸润性幽默的性质可以通过关节的颜色、症状、冷热作用、药物作用以及患者的年龄、饮食、运动的数量和质量、洗澡的态度等信息来诊断。根据盖伦的说法,治疗需要立即在肘部进行静脉切除放血,这可以重复。此外,还需要清除、灌肠和/或催吐剂来排出幽默。膏药起到了排空幽默的作用,同时也起到了润肤软化的作用。
{"title":"[Gout From the Corpus Hippocraticum to the Renaissance: The Role of Galen].","authors":"Natale Gaspare De Santo, Carmela Bisaccia, Luca Salvatore De Santo","doi":"10.69097/42-02-2025-14","DOIUrl":"https://doi.org/10.69097/42-02-2025-14","url":null,"abstract":"<p><p>Gout is a common, complex, systemic and well-studied form of chronic inflammatory arthritis due to deposition of sodium monourate crystals in peripheral joints and periarticular tissues driven by hyperuricemia. Gout is the oldest recorded inflammatory arthritis to affect humankind, with roots stretching back to 2640 BCE. To establish the timeline of gout from the Corpus Hippocraticum to the Renaissance, this study focuses on Galen (129-c.215 CE). A princeps English edition of Galen's works is still lacking; therefore, this paper provides a translation of the paragraph on gout from the Latin edition [12] by Carolus Gottlob Kühn (Leipzig, 1821-1833). Galen departs from Hippocrates and displays a vast knowledge of pathogenesis, symptomatology, clinical course, differential diagnosis, therapeutic skills and prognostication. In Galen's view, gout is due to fluid overflow that infiltrates nerves and causes pain. Overflowing fluid may be blood, phlegm, or a mixture of bile, blood, and phlegm. The prevailing humor is crude, mucous, and thick, and by residing in the joint, causes tophi. The nature of infiltrating humor can be diagnosed through color of the joint, symptoms, effects of heat and cold, effects of drugs, and information related to age, diet, quantity and quality of exercise, attitude towards baths of the patient. Treatment, according to Galen, required immediate bloodletting by venesection at the elbow, which could be repeated. Purges, enemas, and/or emetics are additionally needed to evacuate the humor(s). Poultices played a role draining the humor(s) as well as for their emollient-softening properties.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1